RRR-alpha-tocopheryl succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways

Nutrition and Cancer
K IsraelKimberly Kline

Abstract

The RRR-alpha-tocopheryl succinate derivative of vitamin E, referred to as vitamin E succinate (VES), inhibits the proliferation of three metastatic human prostatic cancer cell lines, LNCaP, PC-3, and DU-145. LNCaP is a lymph node-derived androgen-sensitive prostate cell line; these cells are defective for response to transforming growth factor-beta (TGF-beta) but are normal for cell cycle-related tumor suppressor genes: p53 and retinoblastoma (Rb). PC-3 is a bone marrow-derived androgen-insensitive prostate cell line; these cells are defective for both p53 alleles but normal for both Rb alleles. DU-145 is a brain-derived androgen-insensitive prostate cell line; these cells are defective for both p53 and both Rb alleles. VES at 5, 10, and 20 micrograms/ml inhibited DNA synthesis in the three cell lines in a dose-dependent manner. Purified TGF-beta 1 at 1 ng/ml inhibited DNA synthesis of PC-3 cells within 24-72 hours and DU-145 cells at 72 hours but did not inhibit DNA synthesis of LNCaP cells. Previous studies in our laboratory showed that VES growth-inhibited tumor cells secrete biologically active antiproliferative factor TGF-beta s, suggesting that VES's mechanism of growth inhibition may involve the TGF-beta system of growt...Continue Reading

References

Oct 1, 1992·Journal of the American College of Nutrition·K N Prasad, J Edwards-Prasad
Nov 22, 1991·Science·R A Weinberg
Jan 1, 1991·Cold Spring Harbor Symposia on Quantitative Biology·C S MurphyH L Moses
Jan 1, 1991·Journal of Surgical Oncology·S J RubinR R Weichselbaum
Apr 1, 1990·The Journal of Cell Biology·R M LyonsH L Moses
Jan 1, 1990·Annual Review of Cell Biology·J Massagué
Apr 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·Y FurukawaJ D Griffin
Feb 14, 1990·European Journal of Biochemistry·R M Lyons, H L Moses
Mar 1, 1989·Molecular and Cellular Endocrinology·G WildingE Gelmann
Jan 1, 1989·Annual Review of Cell Biology·F CrossH Weintraub
Sep 22, 1989·Cell·J A Cooper, P Whyte
Feb 1, 1980·Urology·M MohiuddinG Strong

❮ Previous
Next ❯

Citations

Apr 10, 2003·Urologic Oncology·Eric A KleinCharles Coltman
May 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yu ZhangShuyuan Yeh
Jul 16, 1997·Journal of the National Cancer Institute·W L Stone, A M Papas
Apr 17, 2008·Molecular Cancer Therapeutics·Minsub Shim, Thomas E Eling
May 6, 2008·Nutrition Journal·Kim J SpaccarotellaTerryl J Hartman
Sep 1, 2006·Expert Opinion on Therapeutic Patents·Steven Attia, George Wilding
Sep 15, 2010·Free Radical Research·Agnieszka AugustyniakNeven Zarković
Dec 31, 2002·Biochemical and Biophysical Research Communications·Jing NiShuyuan Yeh
Sep 28, 2002·The Journal of Urology·Vasundara VenkateswaranLaurence H Klotz
Nov 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sylvie DelanianJean-Louis Lefaix
Jan 28, 2004·Prostate Cancer and Prostatic Diseases·V VenkateswaranL H Klotz
Dec 29, 2005·International Journal of Cancer. Journal International Du Cancer·Mokenge P MalafaKounosuke Watabe
Apr 16, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ulrich SilerKarin Wertz
May 21, 2003·World Journal of Urology·Eric A KleinCharles Coltman
Aug 7, 2017·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Tilahun Ayane DebeleChun-Liang Lo
Apr 15, 2006·The Journal of Nutrition·Jacqueline LimpensWytske M van Weerden
Apr 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yi YinShuyuan Yeh
Mar 1, 2006·Molecular Cancer Therapeutics·Sreenivasa DonapatyMokenge P Malafa

❮ Previous
Next ❯

Related Concepts

Related Feeds